2015 Antineoplastics

DRUG REGIMENS

  • many drug regimens combine antineoplastic agents in an attempt to select different mechanisms of action, resistance mechanisms and toxicities

  • for example:
REGIMEN
MECHANISM OF ACTION
RESISTANCE MECHANISMS
UNIQUE (PRIMARY) TOXICITY
ABVD for Hodgkin's disease
Adriamycin
= Doxorubicin
CCNS
Intercalating agent
P-glycoprotein
Changes in target
Increased inactivation
Cardiotoxicity
Myelosuppression
CCS (G2)
Strand breaks

Increased DNA repair
Increased inactivation

Skin and lungs
(not myelosuppression)
CCS (M)
Antimitotic
P-glycoprotein
Neurotoxicity
Myelosuppression
CCNS
Alkylating agent
Nucleophile production
Increased DNA repair
Myelosuppression
Email: Dr. Janet Fitzakerley | ©2015 University of Minnesota Medical School Duluth | Last modified: 11-apr-15 9:39 AM